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TO THE EDITOR
In the September issue of this journal,
Vergilis et al. (2005) report that the
high-molecular weight-melanoma-asso-
ciated antigen (HMW-MAA) also known
as the melanoma chondroitin sulfate
proteoglycan (MCSP) can be present in
the blood of healthy donors
and melanoma patients. Defining a
threshold of 1XU as elevated by their
double-sandwich ELISA assay they
found significant differences in positiv-
ity for HMW-MAA/MCSP antigen
among controls and melanoma patients
(29 vs 3% positivity). The authors
propose ‘‘shedding of the antigen by
both malignant cells and normal cells
but in greater amount by cancer cells’’
as a mechanism for its appearance in the
serum without specifying possible sources
of the HMW-MAA/MCSP antigen.
Our recently published data demon-
strate circulating melanoma cells as a
potential source of the HMW-MAA/
MCSP antigen found in the serum of
melanoma patients (Figure 1). In our
prospective study, we detected HMW-
MAA/MCSP-positive cells with morpho-
logical features of tumor cells in the
blood of 43 (26%) of 164 melanoma
patients, whereas all 50 controls were
negative (Ulmer et al., 2004). The
malignant origin of the HMW-MAA/
MCSP-positive cells in our study was
demonstrated unambiguously by single-
cell comparative genomic hybridization.
As we noted a faint positivity for the
HMW-MAA/MCSP antigen on few gran-
ulocytes, one might speculate that these
cells may contribute to the low levels of
serum HMW-MAA/MCSP antigen mea-
surable in controls.
In contrast to the study published by
Vergilis et al. (2005), we found a
significant association between a posi-
tive result and the number of tumor
cells detected, respectively, and the
stage of the patient. The presence of
two or more HMW-MAA/MCSP-posi-
tive tumor cells in our study had a
negative impact on survival in patients
with metastatic disease, whereas ele-
vated levels of HMW-MAA/MCSP did
not correlate with the clinical outcome
of patients in the study reported by
Vergilis et al.
The reason for these differences
remains unclear. One might speculate
that patient characteristics (selected
patients included in a vaccination pro-
tocol with a probably low tumor load in
most cases (Vergilis et al., 2005) versus
a broad range of patients including
patients with stage II and III melanoma
with non-resected tumors (Ulmer et al.,
2004)) might account for these differ-
ences.
To further evaluate these results, we
suggest one to include both methods in
future experimental designs.
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LETTER TO THE EDITOR
Figure 1. High-molecular weight-melanoma-associated antigen/melanoma chondroitin sulfate
proteoglycan (HMW-MAA/MCSP)-positive cells (red) may be detected in peripheral blood of melanoma
patients (alkaline phosphatase-anti-alkaline phosphatase; original magnification: 100).
Abbreviations: HMW-MAA, high-molecular weight-melanoma-associated antigen; MCSP, melanoma
chondroitin sulfate proteoglycan
